公开(公告)号：US09840502B2

公开(公告)日：2017-12-12

申请号：US14957097

申请日：2015-12-02

Applicant: AbbVie Inc.

Inventor： Nathaniel Catron ,  Shuang Chen ,  Yuchuan Gong ,  Geoff G. Zhang

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

公开(公告)号：US09637476B2

公开(公告)日：2017-05-02

申请号：US14594742

申请日：2015-01-12

Applicant: AbbVie Inc.

Inventor： Yuchuan Gong ,  Geoff G. Zhang

IPC: C07D405/04 ,  C07C59/50 ,  C07C59/54

CPC classification number: C07D405/04 ,  C07B2200/07 ,  C07B2200/13 ,  C07C59/50 ,  C07C59/54

Abstract: The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.

公开(公告)号：US20150073031A1

公开(公告)日：2015-03-12

申请号：US14133297

申请日：2013-12-18

Applicant: AbbVie Inc.

Inventor： Yuchuan Gong ,  Geoff G. Zhang

IPC: C07D405/04 ,  C07C59/54

CPC classification number: C07D405/04 ,  C07B2200/07 ,  C07B2200/13 ,  C07C59/50 ,  C07C59/54

Abstract: The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.